Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 282

1.

Antiretroviral concentrations in the presence and absence of valproic acid.

Calcagno A, Cusato J, Ferrara M, De Nicolò A, Lazzaro A, Manca A, D'Avolio A, Di Perri G, Bonora S.

J Antimicrob Chemother. 2020 Mar 25. pii: dkaa094. doi: 10.1093/jac/dkaa094. [Epub ahead of print]

PMID:
32211890
2.

Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?"

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2020 Mar 24;64(4). pii: e00315-20. doi: 10.1128/AAC.00315-20. Print 2020 Mar 24. No abstract available.

PMID:
32209563
3.

JC virus DNA in cerebrospinal fluid: insight into clinical significance.

Mornese Pinna S, Trunfio M, Imperiale D, Calcagno A.

Diagn Microbiol Infect Dis. 2020 Feb 13:115017. doi: 10.1016/j.diagmicrobio.2020.115017. [Epub ahead of print] No abstract available.

PMID:
32201111
4.

An Analysis of Recent FDA Oncology Scientific Publications.

Schneider JA, Miklos AC, Onken J, Gong Y, Calcagno AM, Blumenthal GM, Aragon R, Pazdur R.

Oncologist. 2020 Mar;25(3):266-270. doi: 10.1634/theoncologist.2019-0503. Epub 2019 Nov 26.

5.

Calcaneal quantitative ultrasound and urine retinol binding protein in HIV-positive antiretroviral-treated patients in Uganda: a pilot study.

Costa C, Scabini S, Kaimal A, Kasozi W, Cusato J, Kafufu B, Borderi M, Mwaka E, Di Perri G, Lamorde M, Calcagno A, Castelnuovo B.

J Infect Dis. 2020 Feb 28. pii: jiaa088. doi: 10.1093/infdis/jiaa088. [Epub ahead of print]

PMID:
32112093
6.

Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic Supplementation.

Montrucchio C, De Nicolò A, D'Ettorre G, D'Ascenzo F, Lazzaro A, Tettoni M, D'Avolio A, Bonora S, Celani L, Di Perri G, Calcagno A.

Int J Antimicrob Agents. 2020 Jan 25:105908. doi: 10.1016/j.ijantimicag.2020.105908. [Epub ahead of print]

PMID:
31991223
7.

I have got you under my skin.

Lupia T, Scabini S, Stroffolini G, Calcagno A.

Infection. 2020 Apr;48(2):315-316. doi: 10.1007/s15010-020-01389-5. Epub 2020 Jan 9. No abstract available.

PMID:
31919763
8.

Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases.

Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, Galli M, Antinori A, Calcagno A, Girardi E.

Int J Infect Dis. 2020 Mar;92:62-68. doi: 10.1016/j.ijid.2019.12.031. Epub 2019 Dec 27.

9.

Implementing routine physical function screening among elderly HIV-positive patients in Uganda.

Lwanga I, Nabaggala MS, Kiragga A, Calcagno A, Guaraldi G, Lamorde M, Castelnuovo B.

AIDS Care. 2019 Dec 17:1-4. doi: 10.1080/09540121.2019.1703888. [Epub ahead of print]

PMID:
31847531
10.

What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system?

Joseph SB, Trunfio M, Kincer LP, Calcagno A, Price RW.

AIDS. 2019 Dec 1;33 Suppl 2:S171-S179. doi: 10.1097/QAD.0000000000002253.

PMID:
31790378
11.

An Analysis of Recent FDA Oncology Scientific Publications.

Schneider JA, Miklos AC, Onken J, Gong Y, Calcagno AM, Blumenthal GM, Aragon R, Pazdur R.

Oncologist. 2019 Nov 26. pii: theoncologist.2019-0503. doi: 10.1634/theoncologist.2019-0503. [Epub ahead of print]

12.

Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation.

Lupia T, Milia MG, Atzori C, Gianella S, Audagnotto S, Imperiale D, Mighetto L, Pirriatore V, Gregori G, Lipani F, Ghisetti V, Bonora S, Di Perri G, Calcagno A.

AIDS. 2020 Mar 1;34(3):373-380. doi: 10.1097/QAD.0000000000002442.

PMID:
31764071
13.

Prolonged isolation stress accelerates the onset of Alzheimer's disease-related pathology in 5xFAD mice despite running wheels and environmental enrichment.

Peterman JL, White JD, Calcagno A, Hagen C, Quiring M, Paulhus K, Gurney T, Eimerbrink MJ, Curtis M, Boehm GW, Chumley MJ.

Behav Brain Res. 2020 Feb 3;379:112366. doi: 10.1016/j.bbr.2019.112366. Epub 2019 Nov 16.

PMID:
31743728
14.

Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPPO" Cohort.

Focà E, Magro P, Guaraldi G, Riva A, Cattelan AM, De Socio GV, Costa C, Piconi S, Celesia BM, Nozza S, Orofino G, Castagna A, Di Perri G, Castelli F, Calcagno A; GEPPO (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group.

PLoS One. 2019 Oct 17;14(10):e0222225. doi: 10.1371/journal.pone.0222225. eCollection 2019.

15.

Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients.

Cusato J, Calcagno A, Marinaro L, Avataneo V, DʹAvolio A, Di Perri G, Bonora S.

Pharmacogenomics J. 2020 Apr;20(2):202-212. doi: 10.1038/s41397-019-0109-x. Epub 2019 Oct 16.

PMID:
31619748
16.

Using database linkages to measure innovation, commercialization, and survival of small businesses.

Onken J, Miklos AC, Dorsey TF, Aragon R, Calcagno AM.

Eval Program Plann. 2019 Dec;77:101710. doi: 10.1016/j.evalprogplan.2019.101710. Epub 2019 Sep 3.

17.

Geographically-related outcomes of U.S. funding for small business research and development: Results of the research grant programs of a component of the National Institutes of Health.

Onken J, Aragon R, Calcagno AM.

Eval Program Plann. 2019 Dec;77:101696. doi: 10.1016/j.evalprogplan.2019.101696. Epub 2019 Jul 31.

18.

The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes.

Trunfio M, Manini C, Trentalange A, Boghi A, Audagnotto S, Imperiale D, Taraglio S, Bonora S, Di Perri G, Calcagno A.

J Neurovirol. 2019 Dec;25(6):887-892. doi: 10.1007/s13365-019-00769-4. Epub 2019 Jun 18.

PMID:
31214917
19.

'Distal 16p12.2 microdeletion' in a patient with autosomal recessive deafness-22.

Tassano E, Ronchetto P, Calcagno A, Fiorio P, Gimelli G, Capra V, Scala M.

J Genet. 2019 Jun;98(2). pii: 56.

20.

Cerebrospinal fluid biomarkers in patients with central nervous system infections: a retrospective study.

Di Stefano A, Alcantarini C, Atzori C, Lipani F, Imperiale D, Burdino E, Audagnotto S, Mighetto L, Milia MG, Di Perri G, Calcagno A.

CNS Spectr. 2019 May 27:1-7. doi: 10.1017/S1092852919000981. [Epub ahead of print]

PMID:
31130152
21.

Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen.

Armenia D, Di Carlo D, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group.

Antivir Ther. 2019;24(5):321-331. doi: 10.3851/IMP3309.

22.

Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2.

Cusato J, Calcagno A, De Nicolò A, Mogyorosi K, D'Avolio A, Di Perri G, Bonora S.

Diagn Microbiol Infect Dis. 2019 Jun;94(2):202-204. doi: 10.1016/j.diagmicrobio.2018.07.001. Epub 2018 Jul 6.

PMID:
30922593
23.

Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02174-18. doi: 10.1128/AAC.02174-18. Print 2019 Jun. Erratum in: Antimicrob Agents Chemother. 2020 Mar 24;64(4):.

24.

Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda.

Ssebambulidde K, Segawa I, Laker E, Lamorde M, Castelnouvo B, Nakasujja N, Calcagno A.

Oxf Med Case Reports. 2019 Feb 16;2019(2):omy132. doi: 10.1093/omcr/omy132. eCollection 2019 Feb.

25.

The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study.

Calcagno A, Cusato J, Sekaggya-Wiltshire C, von Braun A, Motta I, Turyasingura G, Castelnuovo B, Fehr J, Di Perri G, Lamorde M.

Clin Pharmacol Ther. 2019 Aug;106(2):450-457. doi: 10.1002/cpt.1403. Epub 2019 Mar 29.

PMID:
30779340
26.

Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease.

Pinzone MR, Ceccarelli M, Venanzi Rullo E, Maresca M, Bruno R, Condorelli F, Di Rosa M, Madeddu G, Focà E, Calcagno A, Celesia BM, Cacopardo B, Nunnari G, Pellicanò GF.

Biomed Rep. 2019 Feb;10(2):140-144. doi: 10.3892/br.2019.1183. Epub 2019 Jan 7.

27.

In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis.

Peyracchia M, Verardi R, Rubin SR, Abu-Assi E, Montrucchio C, Perl L, Grossomarra W, Calcagno A, Omedè P, Montefusco A, Bonora S, Moretti C, D'Amico M, Mauro R, D'Ascenzo F.

J Cardiovasc Med (Hagerstown). 2019 May;20(5):321-326. doi: 10.2459/JCM.0000000000000767. Review.

PMID:
30664538
28.

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.

Mondi A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group.

J Int AIDS Soc. 2019 Jan;22(1):e25227. doi: 10.1002/jia2.25227.

29.

A "Tinea" immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment.

Lupia T, Costa C, Forni N, Calcagno A.

G Ital Dermatol Venereol. 2019 Jan 9. doi: 10.23736/S0392-0488.18.06097-2. [Epub ahead of print] No abstract available.

PMID:
30636396
30.

HIV-1 detection in the olfactory mucosa of HIV-1-infected participants.

Bertero L, Joseph SB, Trunfio M, Allice T, Catera S, Imperiale D, Cassoni P, Kincer LP, Pirriatore V, Ghisetti V, Amasio E, Zanusso G, Bonora S, Di Perri G, Calcagno A.

AIDS. 2019 Mar 15;33(4):665-674. doi: 10.1097/QAD.0000000000002102.

PMID:
30608272
31.

SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV.

Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, D'Avolio A, Ciccarelli N, La Monica S, Colafigli M, Delle Donne V, De Marco R, Tamburrini E, Visconti E, Di Perri G, De Luca A, Bonora S, Di Giambenedetto S.

J Antimicrob Chemother. 2019 Apr 1;74(4):1035-1043. doi: 10.1093/jac/dky508.

PMID:
30561642
32.

Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions?

Trunfio M, Pinnetti C, Focà E, Bai F, Maffongelli G, Celani L, Cinque P, Celotti A, Andreoni M, D'Arminio Monforte A, D'Ettorre G, Antinori A, Calcagno A.

AIDS. 2019 Mar 15;33(4):759-762. doi: 10.1097/QAD.0000000000002091.

PMID:
30531317
33.

The clinical pharmacology of integrase inhibitors.

Di Perri G, Calcagno A, Trentalange A, Bonora S.

Expert Rev Clin Pharmacol. 2019 Jan;12(1):31-44. doi: 10.1080/17512433.2019.1553615. Epub 2018 Dec 21. Review.

PMID:
30513008
34.

Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?

Calcagno A, Fiumanò M, Zugna D, Cusato J, Montrucchio C, Marinaro L, Trentini L, Ferrara M, D'Avolio A, Pizzi C, Di Perri G, Bonora S.

Pharmacogenomics J. 2019 Feb;19(1):65-71. doi: 10.1038/s41397-018-0064-y. Epub 2018 Nov 8.

PMID:
30405212
35.

High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.

von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C.

J Antimicrob Chemother. 2019 Jan 1;74(1):135-138. doi: 10.1093/jac/dky379.

PMID:
30239753
36.

Novel CNS malformations and skeletal anomalies in a patient with Beaulieu-boycott-Innes syndrome.

Accogli A, Scala M, Calcagno A, Castello R, Torella A, Musacchia F, Allegri AME, Mancardi MM, Maghnie M, Severino M; Telethon Undiagnosed Diseases Program, Nigro V, Capra V.

Am J Med Genet A. 2018 Dec;176(12):2835-2840. doi: 10.1002/ajmg.a.40534. Epub 2018 Sep 20. Review.

PMID:
30238602
37.

Cerebral white matter Hyperintensities in HIV-positive patients.

Trentalange A, Prochet A, Imperiale D, Cusato J, Tettoni M, Nunnari G, Barco A, Bonora S, Di Perri G, Calcagno A.

Brain Imaging Behav. 2020 Feb;14(1):10-18. doi: 10.1007/s11682-018-9966-1.

PMID:
30238207
38.

The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol.

Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, Calcagno A, Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Previdi G, Blasi F; IRENE Network.

Multidiscip Respir Med. 2018 Aug 9;13(Suppl 1):33. doi: 10.1186/s40248-018-0141-8. eCollection 2018.

39.

CNNM2 homozygous mutations cause severe refractory hypomagnesemia, epileptic encephalopathy and brain malformations.

Accogli A, Scala M, Calcagno A, Napoli F, Di Iorgi N, Arrigo S, Mancardi MM, Prato G, Pisciotta L, Nagel M, Severino M, Capra V.

Eur J Med Genet. 2019 Mar;62(3):198-203. doi: 10.1016/j.ejmg.2018.07.014. Epub 2018 Jul 17.

PMID:
30026055
40.

NIH funding longevity by gender.

Hechtman LA, Moore NP, Schulkey CE, Miklos AC, Calcagno AM, Aragon R, Greenberg JH.

Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):7943-7948. doi: 10.1073/pnas.1800615115. Epub 2018 Jul 16.

41.

Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART).

Merlini E, Iannuzzi F, Calcagno A, Bai F, Trunfio M, d'Arminio Monforte A, Bonora S, Marchetti G.

J Neurovirol. 2018 Dec;24(6):679-694. doi: 10.1007/s13365-018-0661-1. Epub 2018 Jul 9.

PMID:
29987585
42.

Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy.

Scabini S, Trunfio M, Pirriatore V, Imperiale D, Audagnotto S, Bertucci R, Ghisetti V, Cinnirella G, Cistaro A, Perna M, Calcagno A, Di Perri G.

Infez Med. 2018 Jun 1;26(2):160-163.

43.

Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations.

Allegra S, Cardellino CS, Fatiguso G, Cusato J, De Nicolò A, Avataneo V, Bonora S, D'Avolio A, Di Perri G, Calcagno A.

J Clin Pharmacol. 2018 Dec;58(12):1550-1556. doi: 10.1002/jcph.1266. Epub 2018 Jun 6.

PMID:
29873816
44.

Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study.

Focà E, Cavaglià G, Rusconi S, Cascavilla A, Cenderello G, Re A, Casari S, van den Bogaart L, Zinzani PL, Caracciolo D, Di Perri G, Bonito A, Lucchini A, Cassola G, Viale P, Calcagno A.

HIV Med. 2018 Jun 4. doi: 10.1111/hiv.12624. [Epub ahead of print]

45.

Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study.

Peyracchia M, De Lio G, Montrucchio C, Omedè P, d'Ettore G, Calcagno A, Vullo V, Cerrato E, Pennacchi M, Sardella G, Manga P, GrossoMarra W, Vullo F, Fedele F, Biondi-Zoccai G, Moretti C, Vachiat A, Bonora S, Rinaldi M, Mancone M, D'Ascenzo F.

Atherosclerosis. 2018 Jul;274:218-226. doi: 10.1016/j.atherosclerosis.2018.05.001. Epub 2018 May 5.

PMID:
29803160
46.

Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders.

Trunfio M, Vai D, Montrucchio C, Alcantarini C, Livelli A, Tettoni MC, Orofino G, Audagnotto S, Imperiale D, Bonora S, Di Perri G, Calcagno A.

HIV Med. 2018 May 15. doi: 10.1111/hiv.12622. [Epub ahead of print]

PMID:
29761877
47.

Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir.

Focà E, Calcagno A, Bonito A, Cusato J, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Castelnuovo F, Di Perri G, Castelli F, Bonora S.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00309-18. doi: 10.1128/AAC.00309-18. Print 2018 Jul.

48.

The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years.

Guaraldi G, Malagoli A, Calcagno A, Mussi C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Riva A, Focà E, Nozza S, Di Perri G.

BMC Geriatr. 2018 Apr 20;18(1):99. doi: 10.1186/s12877-018-0789-0.

49.

Role of MRI T2-DRIVE in the assessment of pituitary stalk abnormalities without gadolinium in pituitary diseases.

Godano E, Morana G, Di Iorgi N, Pistorio A, Allegri AEM, Napoli F, Gastaldi R, Calcagno A, Patti G, Gallizia A, Notarnicola S, Giaccardi M, Noli S, Severino M, Tortora D, Rossi A, Maghnie M.

Eur J Endocrinol. 2018 Jun;178(6):613-622. doi: 10.1530/EJE-18-0094. Epub 2018 Apr 12.

PMID:
29650689
50.

Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration.

Calcagno A, Pinnetti C, De Nicolò A, Scarvaglieri E, Gisslen M, Tempestilli M, D'Avolio A, Fedele V, Di Perri G, Antinori A, Bonora S.

Br J Clin Pharmacol. 2018 Jun;84(6):1380-1383. doi: 10.1111/bcp.13552. Epub 2018 Mar 15.

Supplemental Content

Loading ...
Support Center